Ligelizumab: A promising option on the horizon for the management of chronic spontaneous urticaria
Chronic spontaneous urticaria may pose challenges for the treatment in some patients. Different options for the management of chronic urticaria include second-generation antihistamines, leukotriene receptor antagonists, omalizumab (anti-IgE antibody), and immunosuppressants. Omalizumab, a monoclonal...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Indian Journal of Drugs in Dermatology |
Subjects: | |
Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=1;spage=12;epage=14;aulast=Godse |